Brighton Jones’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.33M Sell
9,381
-3,449
-27% -$554K 0.02% 417
2026
Q2
$2.16M Sell
12,830
-6,042
-32% -$896K 0.04% 283
2026
Q1
$2.49M Buy
+18,872
New +$2.5M 0.05% 230
2025
Q4
– Sell
-10,216
Closed -$1.43M – 631
2025
Q3
$1.43M Buy
10,216
+7,426
+266% +$1.01M 0.03% 296
2025
Q2
$351K Buy
+2,790
New +$320K 0.01% 662

Other funds holding NBIX

Brighton Jones's NBIX Position: Q3 2026 in Review

Brighton Jones reduced its Neurocrine Biosciences (NBIX) stake by 27% in Q3 2026, selling an estimated $554K and leaving 9,381 shares worth $1.33M. The position accounts for 0.02% of the portfolio, ranked #417.

Brighton Jones first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.49M in Q1 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Brighton Jones held 9,381 shares of Neurocrine Biosciences worth $1.33M as of Q3 2026.
  • Brighton Jones sold 3,449 Neurocrine Biosciences shares in Q3 2026, an estimated $554K.
  • Neurocrine Biosciences made up 0.02% of Brighton Jones's portfolio in Q3 2026, its #417 holding.
  • Brighton Jones first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Brighton Jones's Neurocrine Biosciences position peaked at $2.49M in Q1 2026.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.